NEET MDS Admissions 2024: AFMS Announces availability of 1 Periodontology seat for Priority-III, IV, V Candidates in Upcoming MCC Round

New Delhi- Through a notice, Armed Forces Medical Services (AFMS) has informed that 01 seat in a postgraduate subject i.e. Periodontology at AFMC, Pune is available for Priority-III, IV & V candidates in the next round of MCC counselling. As per the MCC counselling schedule, the next round is to be held from August 12, 2024.

Notice has been released for Priority-IV candidates and Dental Officers sponsored by Military Organisations and other Organisations of the Government of India for admission to Post Graduate Courses (Master of Dental Surgery-MDS) through the National Eligibility and Entrance Test (NEET MDS) Exam 2024 in AFMS Institutions for the academic year 2024.

Also Read: AFMS MBBS Admissions 2024: Know Eligibility Criteria, Selection Process, Seat Matrix, All Details Here

As per the notice, “the window for fresh registration & choice filling for the next round of MCC counselling, as per the schedule published by MCC, candidates are intimated to ensure that their sponsorship certificate and their Admit Card reach this Dte Gen, from their respective Ministry/ HQ of Para Military organisation/ Head office of other GoI organisations, by 10:00 AM on 08 Aug 2024”.

With this, the priority-III candidates will be considered eligible for admission in AFMS Institutions only for those subjects, which are mentioned in their sponsorship certificate as forwarded by the respective sponsoring authority. In case a Priority-III candidate is allotted a seat, during the counselling conducted by the MCC, which is not mentioned in the Sponsorship Certificate forwarded by the sponsoring organisation, admission to AFMS PG Teaching Institutes would not be granted and the candidate would be liable to suffer the consequences.

Furthermore, in the notice, the AFMS has mentioned the official address to which the sponsorship certificates are to be submitted by the respective Ministry/ HQ of the Para Military organizations/ Head office of other GoI organisations and the email ID for communication and queries.

Also Read: NEET PG Admissions 2024: AFMS Extends Document Submission Deadline for Medical Officers, Priority IV Candidates

At the same time, the Priority-IV candidates also need to submit certain documents by e-mail with the subject ‘NEET MDS ROLL NO XYZ: PRIORITY-IV ADMISSION THROUGH NEET MDS 2024’ till 10:00 AM on 08 Aug 2024.

“The window for fresh registration & choice filling for the next round of MCC counselling, as per schedule published by MCC, Priority-IV Candidates ( Ex AFMS SSC Dental Officers within 3 years of release, i.e., not before 01 May 2021) desirous of attending AFMS PG (MDS) admission 2024 are intimated to forward a scanned copy of the documents”, the notice stated.

The documents which Priority-IV candidates need to submit are as follows-

1 NEET MDS-2024 Admit Card.

2 Copy of release order from AFMS by DGAFMS/ Concerned Medical Directorate/ NOC.

3 Score Card.

Meanwhile, while sending the above-mentioned documents candidates also need to specify the following information-

1 E-mail ID registered for NEET MDS-2024 with NBE.

2 Mobile No registered with NBE for NEET MDS-2024.

3 Alternate Mobile No.

After sending the documents, the list of eligible candidates will be sent to MCC by this office on 08 August 2024.

Below is the schedule for the MCC NEET MDS counselling for 2024.

Also Read: Applying for AFMS NEET PG 2024, NEET MDS 2024 admissions this year, know eligibility criteria, required documents, counselling details

SCHEDULE

S.NO

SCHEDULE FOR ADMISSION

ALL INDIA QUOTA/DEEMED & CENTRAL UNIVERSITIES

SHARING OF JOINED CANDIDATE’S DATA BY MCC

STATE COUNSELLING

SHARING OF JOINED CANDIDATE’S DATA BY STATES

1

Ist Round of Counselling.

1st July, 2024 to 10th July, 2024.

19th July, 2024.

10th July to 20th July, 2024.

26th July to 27th July, 2024.

2

Last date of Joining.

The last date of Joining is 17th July 2024.

–

25th July, 2024.

–

3

2nd round of Counselling.

7 th Aug, 2024

–

12th Aug, 2024.

–

4

Round-3.

12th Aug to 21st Aug, 2024.

29th Aug., 2024.

21st Aug 2024 to 26th Aug, 2024.

31st Aug.,2024.

5

Last date of joining.

28th Aug., 2024.

–

30th Aug., 2024.

–

6

Stray Vacancy.

2nd Sept., 2024 to 7th Sept., 2024.

–

5th Sept., 2024 to 10th Sept., 2024.

–

7

Last date of joining.

14th Sept., 2024.

–

14th Sept., 2024.

–

To view the notices, click the link below

https://medicaldialogues.in/pdf_upload/priority-iv-246032.pdf
https://medicaldialogues.in/pdf_upload/dental-officers-246033.pdf

Powered by WPeMatico

Over 3 crore people screened for sickle cell anaemia under National Mission: MoS Health informs Parliament

New Delhi: Over 3 crore population in the 17 identified states in the country have been screened for sickle cell anaemia disease till June 30, 2024, the Union Minister of State for Health Shri Prataprao Jadhav informed the Lok Sabha last week.  

The Minister informed that Sickle cell disease is a genetic blood disease that affects the whole life of the patient. It is more common in the tribal population of India but occurs in non-tribals too. It not only causes anaemia but also pain crisis, reduces growth and affects many organs like the lungs, heart, kidneys, eyes, bones and the brain.

Also read- World Sickle Cell Day: Union Tribal Affairs Minister to Lead National Conclave on Raising Awareness

This statement was made in response to questions raised by Shri Haribhai Patel who sought to know whether the Government has suitably addressed the health challenges posed by sickle cell disease, particularly among the tribal population of the country and if so, the details thereof; the details of the number of tribals who have been screened for sickle cell anaemia out of expected screening target of 8 crore under forty years of age in the next three years under the National Sickle Cell Anaemia Elimination Programme; and the details of the efforts being made by the Government for successfully attaining the aforementioned target of screening of about 8 crore tribals.

In response to these questions, MoS Health said in a written statement, “To eliminate sickle cell disease, Sickle Cell Anaemia Elimination Mission has been launched by Hon’ble Prime Minister from Madhya Pradesh on 1st July 2023. The objectives of the Mission are the provision of affordable, accessible and quality care to all Sickle Cell Diseased patients, reduction in the prevalence of Sickle Cell Disease through awareness creation, and targeted screening of 7 crore people till year 2025-26 in the age group of 0-40 years in affected 278 districts of tribal areas and counselling through collaborative efforts of central ministries and State governments. Till 30.06.2024, a total of 3,55,50,230 population in the 17 identified States have been screened and uploaded on the portal by States.”

Further, he shared a National Sickle Cell portal – https://sickle.nhm.gov.in where the achievement of screening can be accessed.

Through the Ministry of Tribal Affairs, awareness and counselling material have been developed. IEC and media activities are adopted for the propagation of awareness of disease, screening and management. State Governments have to play an important role in the implementation of mission activities, the Minister added.  

Powered by WPeMatico

The health benefits of seaweed—a bath full of bladderwrack might be just what the doctor ordered

Seaweed, the colorful macroalgae that grows in the ocean, is a food source for marine life and humans. Each type of seaweed has a unique set of nutrients and can boost vitamin and mineral intake if eaten regularly.

Powered by WPeMatico

Study compares surgical techniques for Crohn disease

For patients undergoing open or laparoscopic resection of the small bowel or strictureplasty for Crohn disease (CD), small bowel resection is associated with the longest length of stay and increased odds of postoperative wound complications, according to a study published online July 29 in the International Journal of Colorectal Disease.

Powered by WPeMatico

Report suggests nearly half of dementia cases could be prevented or delayed by tackling 14 risk factors

Addressing 14 modifiable risk factors, starting in childhood and continuing throughout life, could prevent or delay nearly half of dementia cases, according to a new report led by UCL researchers.

Powered by WPeMatico

Strengthening global regulatory capacity for equitable access to vaccines in public health emergencies

Three high-impact steps could be taken by global health leaders to reshape the global regulatory framework and help address the pressing need for equitable access to diagnostics, therapeutics, and vaccines during public health emergencies, according to a Georgetown global health law expert and a medical student.

Powered by WPeMatico

Over 29,000 Hospitals empanelled under Ayushman Bharat Pradhan Mantri Jan Arogya Yojana as of June 2024

New Delhi: As of 30.06.2024, more than 34.7 crore Ayushman cards have been created under Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) in the country. 

State/UT-wise details of Ayushman cards created under AB-PMJAY are in Annexure I. The scheme is implemented in 33 States/UTs except the NCT of Delhi, West Bengal, and Odisha.

As of 30.06.2024, a total number of 7.37 crore hospital admissions worth Rs. One lakh crore have been authorized under the scheme. State/UT-wise details of the number of authorized hospital admissions under the scheme are in Annexure II.

Also Read:Free medical treatment to all citizens above age 70 under Ayushman Bharat Scheme: President Murmu

Beneficiaries eligible under the scheme can create their Ayushman card at any time i.e. throughout the year. Eligible beneficiaries can either create the card themselves using Ayushman App or visit the nearest CSC or empanelled hospital to create their Ayushman card.

AB-PMJAY aims to provide health cover of Rs. 5 lakhs per family per year for secondary and tertiary care hospitalization to approximately 55 crore beneficiaries corresponding to 12.34 crore families constituting the bottom 40% of India’s population.

Eligible beneficiaries can avail of cashless and paperless healthcare services related to hospitalization across more than 29,000 empanelled hospitals in the country. In the latest national master of the Health Benefit Package (HBP), the scheme provides cashless healthcare services related to 1949 procedures across 27 medical specialties including General Medicine, Surgery, Cardiology, Oncology, etc.

State/UT-wise details of Ayushman cards created under AB-PMJAY

State/UT

No. of Ayushman cards(in lakh)

Andaman And Nicobar Islands

0.72

Andhra Pradesh

155.67

Arunachal Pradesh

1.41

Assam

174.37

Bihar

295.26

Chandigarh

1.88

Chhattisgarh

222.01

Dadra And Nagar Haveli Daman And Diu

0.14

Goa

0.82

Gujarat

255.95

Haryana

119.84

Himachal Pradesh

13.27

Jammu And Kashmir

85.94

Jharkhand

121.95

Karnataka

171.46

Kerala

76.70

Ladakh

1.89

Lakshadweep

0.35

Madhya Pradesh

402.45

Maharashtra

279.90

Manipur

6.13

Meghalaya

19.76

Mizoram

5.63

Nagaland

7.15

Puducherry

5.09

Punjab

87.97

Rajasthan

217.10

Sikkim

0.77

Tamil Nadu

73.59

Telangana

82.51

Tripura

19.61

Uttar Pradesh

511.16

Uttarakhand

57.08

State/UT-wise details of the number of authorized hospital admissions under AB-PMJAY

State/UT

Number of authorized hospital admissions

Andaman And Nicobar Islands

2,912

Andhra Pradesh

6,549,443

Arunachal Pradesh

2,807

Assam

1,138,225

Bihar

1,130,122

Chandigarh

50,749

Chhattisgarh

6,036,955

DNH & DD

129,002

Goa

7,105

Gujarat

5,537,440

Haryana

1,560,290

Himachal Pradesh

280,605

Jammu And Kashmir

1,313,376

Jharkhand

2,094,180

Karnataka

8,693,558

Kerala

6,265,298

Ladakh

15,381

Lakshadweep

1,065

Madhya Pradesh

4,278,784

Maharashtra

1,941,236

Manipur

164,850

Meghalaya

822,207

Mizoram

130,184

Nagaland

72,703

Puducherry

89,511

Punjab

2,136,925

Rajasthan

5,420,065

Sikkim

20,520

Tamil Nadu

10,371,732

Telangana

1,662,356

Tripura

336,073

Uttar Pradesh

4,356,280

Uttarakhand

1,168,945

The Union Minister of State for Health and Family Welfare, Shri Prataprao Ganpatrao Jadhav stated this in a written reply in the Lok Sabha today.

Also Read:eSwasthya Dham Portal integrates with Ayushman Bharat Digital Mission for pilgrim health monitoring

Powered by WPeMatico

Gujarat NEET Counselling for MBBS, BDS, AYUSH Admissions begins, Apply now

Gujarat- The Admission Committee for Professional Undergraduate Medical Educational Courses (ACPUGMEC) of Gujarat is inviting applications for admission to MBBS, BDS, BAMS and BHMS courses for the academic year 2024-25.

According to the notice, the Schedule for Online Registration and Document verification for the admission to above Courses in Government, Grant in aid and Self-financed Medical, Dental, Ayurvedic and Homeopathy Colleges (*including 15% All India quota seats of BAMS & BHMS courses in Self-financed colleges) after Qualifying Examination of 12th Standard (Science Stream with B / AB Group) passed from Gujarat Board OR the school situated in Gujarat State from the Central Board, Council of Indian School Certificate Examination, Cambridge University and National Institute of Open Schooling and after qualifying as per All India Rank in NEET-UG 2024 and eligible as per Admission Rules of Health and Family Welfare Department, Govt. of Gujarat and respective commission/council will be held as follows:

Also Read: Gujarat MDS Admissions 2024: 224 seats available for candidates, choice filling till July 20th

As per the schedule, the online registration has started and will be valid till 05:00 PM on 13 August 2024. After this, the document verification process will start from 05 August 2024, 10:00 AM till 14 August 2024, 04:30 PM. Below is the complete schedule-

SCHEDULE

S.NO

DETAILS

DATE AND TIME

FROM

TO

1

Online PIN purchase from the website of the admission committee.

03/08/2024 10:00 am

13/08/2024 02:00 pm

2

For Online Registration.

03/08/2024 10:00 am

13/08/2024 05:00 pm

3

Documents Verification and Submission of photocopies of Documents at the Help Center.

05/08/2024 10:00 am

14/08/2024 04:30 pm

STEPS FOR ONLINE REGISTRATION

STEP 1- Filling out NEET-UG and 12th details and authentication through PIN.

STEP 2- Filling out the Candidate’s other details.

STEP 3- Password generation.

STEP 4- Confirmation of filled details.

STEP 5- Take a Printout of Registration Details.

After online Registration, the candidate has to take a prior appointment for the Documents Verification and Submission of self-attested photocopies of Documents at the Help Center. Candidates, themselves can select the Date and Help Center for Documents verification at the time of printing the Registration Slip.

Also Read: DME Gujarat Invites Applications for NEET MDS Admissions 2024, Know schedule, eligibility criteria, registration process here

All candidates must verify all the original documents at designated help centres and obtain a registration slip, without which the candidate will not be eligible for further admission process. Below is the list of the documents to be submitted-

DOCUMENTS

1 Standard 10th (SSC) mark sheet and Standard 12th (HSC) mark sheet.

2 NEET-UG mark-sheet of the current academic year.

3 Proof of Birth Place.

4 Proof of Birth Date.

5 Certificates for Candidates Born Outside Gujarat.

6 Certificates for Scheduled Caste (SC) candidates.

7 Certificates for Scheduled Tribes (ST) candidates.

8 Certificates for Socially and Educationally Backward Classes (SEBC) candidates.

9 Certificates for Economically Weaker Sections (EWS)candidate.

10 Certificates for Person with Disability (PwD) candidates.

11 Certificates for local candidates of Ahmedabad.

12 Certificates for local candidates of Surat.

13 Certificates for Overseas Citizen of India (OCI) candidates.

14 Certificate of Physical Fitness.

Meanwhile, for online registration, the PIN can be purchased online from the official website of DME Gujarat by paying Rs. 1000/- (non-refundable) + Rs. 10,000 (refundable security deposit) = Total Rs. 11,000/-.

For admission to 15% All India Quota seats of 1st-year undergraduate courses in Medical, Dental, Ayurvedic and Homeopathy for the academic year 2024-25, candidates must have passed 12th from Science stream with B/AB group from a school situated anywhere in India from any examination board in India and must be eligible as per the admission rules of the Ministry of AYUSH, Government of India and the concerned Commission/Council after qualifying as per All India Rank in NEET-UG 2024.

FOR LOCAL QUOTA

Candidates who want to apply for Local Quota Seats of Smt. NHL Municipal Medical College, Ahmedabad or Surat Municipal Institute of Medical Education & Research (SMIMER), Surat candidate must obtain a certificate that he/she is a local student of Ahmedabad/Surat city from the Dean of the respective institute, for this candidate has to contact the respective college during the online registration.

FOR NRI CANDIDATES

After online application, the NRO candidates have to submit a Demand Draft of Rs.10,000/- in favor of “ACPUGMEC”, payable at Gandhinagar as a processing fee at the office of ACPUGMEC, GMERS Medical College, Gandhinagar Only.

After the registration process, ACPUGMEC will prepare and declare a merit list of all eligible candidates and after the declaration of the merit list, the candidate needs to verify the merit number and category as mentioned in the registration details.

Along with this, the choice filling will be initiated online for each round. Once the choice-filling period is over, the ACPUGMEC will process for allotment of seats and declare the status of allotment on the website. The candidates can view their status of allotment by logging through their own User ID.

To view the schedule, click the link below

https://medicaldialogues.in/pdf_upload/acppgmec-gujarat-invites-applications-for-15-all-india-quota-seats-in-medical-dental-ayurvedic-homeopathy-courses-for-2024-25-registration-starts-today-246182.pdf

Powered by WPeMatico

EMA Committee recommends Rybrevant in combo with chemotherapy for adult patients with lung cancer after failure of prior therapy

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a Type II extension of indication for RYBREVANT (amivantamab) in combination with chemotherapy (carboplatin and pemetrexed), for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (ex19del) or Exon 21 L858R substitution (L858R) mutations, after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).

“Resistance mechanisms after disease progression on osimertinib are diverse and polyclonal, with up to half being EGFR and MET-based alterations. There are no targeted therapies approved for the post-osimertinib setting, and outcomes with the current standard of care, platinum-based chemotherapy, are poor,” said Antonio Passaro, M.D., Ph.D., Medical Oncologist, Division of Thoracic Oncology at the European Institute of Oncology in Milan, Italy*. “The combination of amivantamab and chemotherapy offers renewed hope and a new standard of care for these patients, with improvements observed in response rates, progression-free survival, and intracranial efficacy, even in patients with previously untreated brain metastases.”

“EGFR gene mutations are the most common actionable oncogenic mutations in NSCLC, with ex19del or L858R mutations representing up to 90 percent of all EGFR mutations,” said Henar Hevia, Ph.D., Senior Director, EMEA Therapeutic Area Lead, Oncology, Johnson & Johnson Innovative Medicine. “At Johnson & Johnson, our dedication to transforming the treatment of lung cancer with innovative therapies is unwavering, and we are proud to take another step forward for patients in need of new, targeted treatment options.”

The CHMP recommendation for amivantamab is supported by data from the Phase 3 MARIPOSA-2 (NCT04988295) study, evaluating the efficacy and safety profile of amivantamab and chemotherapy in patients with locally-advanced or metastatic EGFR ex19del or L858R substitution NSCLC who had disease progression on or after treatment with osimertinib. The amivantamab plus chemotherapy arm met its primary endpoint, significantly reducing the risk of disease progression or death by 52 percent, compared to chemotherapy alone, with a median progression-free survival (PFS) of 6.3 months, versus 4.2 months (hazard ratio [HR]=0.48; 95 percent confidence interval [CI], 0.36–0.64; P<0.001). Additionally, amivantamab plus chemotherapy showed an objective response rate (ORR) of 64 percent, compared to 36 percent with chemotherapy alone.

The data from MARIPOSA-2 also showed that amivantamab combination regimens may provide intracranial activity, critical for a disease where nearly 30 percent of patients develop brain metastases. Specifically, amivantamab plus chemotherapy reduced the risk of intracranial progression or death by 45 percent compared to chemotherapy alone, with a median intracranial progression-free survival of 12.5 versus 8.3 months (HR=0.55; 95 percent CI, 0.38–0.79; P=0.001).

The safety profile of amivantamab plus chemotherapy is consistent with that of its individual components. 

“The positive CHMP opinion is welcome news and demonstrates the results of our deep commitment to transforming outcomes for patients with NSCLC,” said Kiran Patel, M.D., Vice President, Clinical Development, Solid Tumours, Johnson & Johnson Innovative Medicine. “Amivantamab has already shown positive outcomes in treating patients with other EGFR mutations, and we now look forward to the next steps in making it available to further patients with common EGFR mutations after progression on osimertinib”

Results from MARIPOSA-2 were presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO) 2023 Congress and simultaneously published in the Annals of Oncology.

Read also: JnJ gets USFDA nod for Darzalex Faspro-based quadruplet regimen for newly diagnosed multiple myeloma who are transplant-eligible

Powered by WPeMatico